Sanofi awaits FDA inspection of fill/finish plant before Q1 Kevzara resubmission
Sanofi intends to resubmit its licensing application for Kevzara within the next few weeks following subject to a US FDA re-inspection of a French fill/finish plant.
News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs